Annotator,Drug Name,Experimental evidence,Identifier,Reference,Reference (2),Reference (3),SMILES,Score
Patrick,Mesalazine,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov001,https://www.nature.com/articles/s41421-020-0153-3,,,C1=CC(=C(C=C1N)C(=O)O)O,0
Patrick,Toremifene,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov002,https://www.nature.com/articles/s41421-020-0153-3,,,CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3,0
Patrick,Eplerenone,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov003,https://www.nature.com/articles/s41421-020-0153-3,,,C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC,0
Patrick,Paroxetine,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov004,https://www.nature.com/articles/s41421-020-0153-3,,,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,0
Patrick,Sirolimus,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov005,https://www.nature.com/articles/s41421-020-0153-3,,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,0
Patrick,Dactinomycin,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov006,https://www.nature.com/articles/s41421-020-0153-3,,,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C,0
Patrick,Ibesartan,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov007,https://www.nature.com/articles/s41421-020-0153-3,,,[2H]C1=C(C(=C(C(=C1CN2C(=NC3(C2=O)CCCC3)CCCC)[2H])[2H])C4=CC=CC=C4C5=NNN=N5)[2H],0
Patrick,Mercaptopurine,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov008,https://www.nature.com/articles/s41421-020-0153-3,,,C1=NC2=C(N1)C(=S)N=CN2,0
Patrick,Melatonin,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov009,https://www.nature.com/articles/s41421-020-0153-3,,,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,0
Patrick,Quinacrine,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov010,https://www.nature.com/articles/s41421-020-0153-3,,,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,0
Patrick,Carvedilol,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov011,https://www.nature.com/articles/s41421-020-0153-3,,,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,0
Patrick,Colchicine,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov012,https://www.nature.com/articles/s41421-020-0153-3,,,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,0
Patrick,Camphor,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov013,https://www.nature.com/articles/s41421-020-0153-3,,,CC1(C2CCC1(C(=O)C2)C)C,0
Patrick,Equilin,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov014,https://www.nature.com/articles/s41421-020-0153-3,,,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)O)[C@@H]1CCC2=O,0
Patrick,Oxymetholone,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov015,https://www.nature.com/articles/s41421-020-0153-3,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,0
Patrick,Emodin,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov016,https://www.nature.com/articles/s41421-020-0153-3,,,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O,0
Patrick,Sirolimus + Dactinomycin,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov017,https://www.nature.com/articles/s41421-020-0153-3,,,,0
Patrick,Toremifene + Emodin,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov018,https://www.nature.com/articles/s41421-020-0153-3,,,,0
Patrick,Mercaptopurine + Melatonin,"None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).",cov019,https://www.nature.com/articles/s41421-020-0153-3,,,,0
Miquel/Gemma,6-fluoro-3-hydroxy-2-pyrazinecarboxamide,Developed as antiinfluenza,cov020,https://www.ncbi.nlm.nih.gov/pubmed/28769016,https://www.dailysabah.com/life/health/japanese-drug-favipiravir-proving-effective-against-covid-19-in-as-little-as-4-days,,C1=C(N=C(C(=O)N1)C(=O)N)F,3
Miquel/Gemma,GS-5734,Decreases monkey infection by MERS-CoV,cov021,https://www.pnas.org/content/early/2020/02/12/1922083117,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR1DeWaS1w2LD3MrW,,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,3
Miquel/Gemma,Toremifene citrate,Effective against SARS-CoV MERS-CoV in vitro / inhibits EVOB entry in cells / identified in network screening,cov022,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/,https://stm.sciencemag.org/content/5/190/190ra79,https://www.nature.com/articles/s41421-020-0153-3,CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3,1
Miquel/Gemma,Chloroquine diphosphate,Anti SARS-CoV and MERS-CoV in vitro,cov023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071,https://www.sciencedirect.com/science/article/pii/S0883944120303907,https://www.ncbi.nlm.nih.gov/pubmed/32074550,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O.OP(=O)(O)O,3
Miquel/Gemma,Loperamide,Anti SARS-CoV and MERS-CoV in vitro,cov024,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733787/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071/,,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,1
Miquel/Gemma,Used for MERS clinically / No effect in clinical trial for Covid19,Anti SARS-CoV and MERS-CoV in vitro / NO EFFECT IN CLINICAL TRIAL,cov025,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071/,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282,,CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O,-1
Miquel/Gemma,Chlorpromazine hydrochloride,Effective against SARS-CoV and MERS-CoV in vitro,cov026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071/,,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,1
Miquel/Gemma,Triflupromazine hydrochloride,Effective against SARS-CoV and MERS-CoV in vitro,cov027,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/,,,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F,1
Miquel/Gemma,Imatinib mesylate,Effective against SARS-CoV and MERS-CoV in vitro,cov028,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/,https://jvi.asm.org/content/90/19/8924,,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,1
Miquel/Gemma,Dasatinib,Effective against SARS-CoV and MERS-CoV in vitro,cov029,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/,,,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,1
Miquel/Gemma,Gemcitabine hydrochloride,Effective against SARS-CoV and MERS-CoV in vitro,cov030,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/,,,C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F.Cl,1
Miquel/Gemma,Equilin,inhibits EVOB entry in cells / identified in network screening,cov031,https://stm.sciencemag.org/content/5/190/190ra79,https://www.nature.com/articles/s41421-020-0153-3,,C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)O)[C@@H]1CCC2=O,1
Miquel/Gemma,Irbesartan,identified in network screening,cov032,https://www.nature.com/articles/s41421-020-0153-3,,,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,1
Miquel/Gemma,Sirolimus,MERS-CoV 60% decreased infection in vitro / improved clinical outcome H1N1,cov033,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733787,https://www.ncbi.nlm.nih.gov/pubmed/24105455,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,2
Miquel/Gemma,Melatonin,Prolongs survival due to anti inflammation (not virus related),cov034,https://www.nature.com/articles/s41421-020-0153-3,,,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,1
Miquel/Gemma,Eplerenone,"Prolongs survival, tested in viral myocarditis in mice",cov035,https://www.ncbi.nlm.nih.gov/pubmed/19213804,,,C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC,1
Miquel/Gemma,Teicoplanin,Blocks cell entry of Covid-19 in vitro,cov036,https://www.biorxiv.org/content/10.1101/2020.02.05.935387v1.abstract,https://www.ncbi.nlm.nih.gov/pubmed/30170320,,CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O,1
Miquel/Gemma,Ribavirin,Combined with IFNalpha improves MERS-Cov,cov037,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)70920-X/fulltext,,,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,3
Miquel/Gemma,Penciclovir,Used in Herpex treatment,cov038,https://pubchem.ncbi.nlm.nih.gov/compound/Penciclovir,,,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,2
Miquel/Gemma,Galidesivir,"High efficacy in vitro for filoviruses, under clinical trials",cov039,https://www.ncbi.nlm.nih.gov/pubmed/24590073,,,C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O,1
Miquel/Gemma,Disulfiram,In vitro inhibition of SARS and MERS enzymes,cov040,https://www.ncbi.nlm.nih.gov/pubmed/29289665,,,CCN(CC)C(=S)SSC(=S)N(CC)CC,1
Miquel/Gemma,Ritonavir,Used for MERS clinically / No effect in clinical trial for Covid19,cov041,https://www.nejm.org/doi/full/10.1056/NEJMoa2001282,https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3846-x,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,-1
Miquel/Gemma,Darunavir,Not clear if clinical trial ongoing,cov042,https://www.pharmaceutical-technology.com/news/jj-janssen-darunavir-coronavirus/,,,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,1
Miquel/Gemma,Favilavir,,cov043,https://www.upi.com/Health_News/2020/02/17/China-approves-antiviral-favilavir-to-treat-coronavirus/5291581953892/,,,C1=C(N=C(C(=O)N1)C(=O)N)F,3
Miquel/Gemma,Oseltamivir,"Ongoing trial, used for influenza A and B",cov044,https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx,,,CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC,3
Miquel/Gemma,ASC09F,Ongoing trial in combination with oseltamivir,cov045,,,,,3
Miquel/Gemma,Nafamostat,"effective against MERS, COVID19",cov046,https://www.nature.com/articles/s41422-020-0282-0,,,C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,1
Miquel/Gemma,Griffithsin,Effective in vitro and in vivo against SARS,cov047,https://www.ncbi.nlm.nih.gov/pubmed/20032190,https://www.ncbi.nlm.nih.gov/pubmed/24145548,,,1
Miquel/Gemma,Resveratrol,In principle inhibits MERS infection...,cov048,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2253-8,,,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,1
Miquel/Gemma,Umifenovir,"Used in influenza treatment, only approved in Russia, clinical assays for COVID 19 ongoing",cov049,https://pubmed.ncbi.nlm.nih.gov/15266832/,,,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,3
Miquel/Gemma,Mefloquine,Effective against MERS and SARS in vitro,cov050,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/,,,C1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O,1
Miquel/Gemma,Amodiaquine,Effective against MERS and SARS in vitro / used in EBOLa,cov051,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934550/,,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,2
Miquel/Gemma,Ifenprodil (maybe enters clinical trial),Improves survival of H5N1 infected mice,cov052,https://www.ncbi.nlm.nih.gov/pubmed/31822599,,,CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3,3
Miquel/Gemma,TMPRSS2 inhibitor (not disclosed),effectively blocks cell entry of COVID19,cov053,https://www.sciencedirect.com/science/article/pii/S0092867420302294,,,,1
Miquel/Gemma,6'-Fluorinated Aristeromycin Analog,Broad spectrum in vitro against RNA viruses,cov054,https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00781,,,,1
Miquel/Gemma,Acyclovir Fleximer analogues,In vitro effective against MERS,cov055,https://www.ncbi.nlm.nih.gov/pubmed/26048809,,,,1
Miquel/Gemma,Thiopurine analogues,In vitro inhibition of MERS PLp,cov056,https://www.sciencedirect.com/science/article/pii/S0166354214003623,,,,1
Miquel/Gemma,Compound 6,In vitro inhibition of MERS PLp,cov057,https://www.ncbi.nlm.nih.gov/pubmed/30940566,,,,1
Miquel/Gemma,GC376,Cures a coronavirus-like disease in felines,cov058,https://www.ncbi.nlm.nih.gov/pubmed/27027316,,,CC(C)C[C@@H](C(=O)N[C@@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2=CC=CC=C2.[Na+],1
Miquel/Gemma,GC813,Computer based design of MERS 3CLpro inhibitor,cov059,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891363/,,,,1
Miquel/Gemma,Phenylisoserine inhibitors,Computer based design of SARS 3CLpro inhibitor,cov060,https://www.ncbi.nlm.nih.gov/pubmed/28454669,,,,1
Miquel/Gemma,Peptidomimetic inhibitors,Antiviral effect in vitro against SARS and MERS,cov061,https://www.ncbi.nlm.nih.gov/pubmed/28216367,,,,1
Miquel/Gemma,"1,2,3-triazoles",Computer based design of SARS 3CLpro inhibitor,cov062,https://www.sciencedirect.com/science/article/pii/S0960894X18307509,,,,1
Miquel/Gemma,Neuraminidase inhibitor analogues,Computer based design of SARS 3CLpro inhibitor,cov063,https://www.ncbi.nlm.nih.gov/pubmed/27240464,,,,1
Miquel/Gemma,Unsymmetric aromatic disulfides,In vitro inhibition of SARS Mpro,cov064,https://www.sciencedirect.com/science/article/pii/S0223523417304063,,,,1
Miquel/Gemma,Pyrithiobac derivatives,"In vitro inhibition of SARS Mpro, they derive from herbicides",cov065,https://www.ncbi.nlm.nih.gov/pubmed/30784880,,,,1
Miquel/Gemma,"2,6-Bis-arylmethyloxy-5-hydroxychromones",In vitro validation against SARS enzymes,cov066,https://www.ncbi.nlm.nih.gov/pubmed/21925774,,,,1
Miquel/Gemma,SSYA10-001,In vitro validation against SARS and MERS,cov067,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136041/,,,ON(=O)C1=C(SCC2=NNC(=S)N2CC=C)C=CC=C1,1
Miquel/Gemma,Triazol derivatives,FRET against MERS enzyme,cov068,https://www.ncbi.nlm.nih.gov/pubmed/31955138,,,,1
Miquel/Gemma,Nitazoxanide,"Induces interferon production, works in influenza",cov069,https://www.ncbi.nlm.nih.gov/pubmed/25108173,,,CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-],3
Miquel/Gemma,Recombinant interferons,,cov070,,,,,0
Miquel/Gemma,Cyclosporine A,Reduces MERS infection in human in vitro ex vivo,cov071,https://www.ncbi.nlm.nih.gov/pubmed/29772254,https://www.ncbi.nlm.nih.gov/pubmed/23620378,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,2
Miquel/Gemma,Alisporivir,Prevents in vitro MERS/SARS infection but not in mouse model,cov072,https://www.ncbi.nlm.nih.gov/pubmed/27840112,,,CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C,1
Miquel/Gemma,Selumetinib,Inhibits MERS replication in vitro,cov073,https://www.ncbi.nlm.nih.gov/pubmed/25487801,,,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO,1
Miquel/Gemma,Trametinib,Inhibits MERS replication in vitro,cov074,https://www.ncbi.nlm.nih.gov/pubmed/25487801,,,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,1
Miquel/Gemma,Rapamycin,Inhibits MERS replication in vitro,cov075,https://www.ncbi.nlm.nih.gov/pubmed/25487801,,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,1
Miquel/Gemma,Saracatinib,Inhibits MERS replication in vitro,cov076,https://www.ncbi.nlm.nih.gov/pubmed/29795047,,,CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl,1
Patrick,Favipiravir,Increases 7-day recovery rate in patients with COVID19,cov077,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1,,,C1=C(N=C(C(=O)N1)C(=O)N)F,3
Patrick,Remdesivir,Same Moa than Favipiravir. Effective in mice and cell lines. CLinical trials ongoing,cov078,https://www.nature.com/articles/s41422-020-0282-0,,,CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,2
Adria,Camostat mesylate,Reduce SARS-Cov2 infection in Calu2 cells.,cov079,https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4,,,O=C(C1=CC=C(NC(N)=N)C=C1)OC2=CC=C(CC(OCC(N(C)C)=O)=O)C=C2.CS(=O)(O)=O,1
Adria,E-64d,Reduce SARS-2-S infection in caco2 and 293T. No data for SARS-Cov2,cov080,https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4,,,O=[C@@](N[C@H]([C@](NCCC(C)C)=O)CC(C)C)[C@H]1O[C@@H]1C(OCC)=O ,1
Miquel/Gemma,Beta-D-N4-hydroxycytidine,"MoA: lethal mutagenesis, effective in vitro against SARS-Cov2 and in mice against SARS-CoV and MERS *BioArx",cov081,https://www.biorxiv.org/content/10.1101/2020.03.19.997890v1,,,,1
Miquel/Gemma,Niclosamide,"MoA: inhibits SKP2 enzyme, tested in Vero cells *BioArx / Effect validated for Sars-CoV in 2003",cov082,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O,1
Miquel/Gemma,Ciclesonide,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov083,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6,0
Miquel/Gemma,Tilorone,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov084,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CCN(CC)CCOC1=CC2=C(C=C1)C3=C(C2=O)C=C(C=C3)OCCN(CC)CC,0
Miquel/Gemma,Cyclosporine,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov085,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0
Miquel/Gemma,Mefloquine,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov086,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,C1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O,0
Miquel/Gemma,Amodiaquine,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov087,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,0
Miquel/Gemma,Proscillaridin,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov088,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O,0
Miquel/Gemma,Digitoxin,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov089,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,0
Miquel/Gemma,Digoxin,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov090,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,0
Miquel/Gemma,Hexachlorophene,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov091,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,0
Miquel/Gemma,Hydroxyprogesterone caproate,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov092,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C,0
Miquel/Gemma,Salinomycin,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov093,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O,0
Miquel/Gemma,Ouabain,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov094,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O,0
Miquel/Gemma,Cepharanthine,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov095,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)C[C@@H]7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3,0
Miquel/Gemma,Oxyclozanide,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov096,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,C1=C(C=C(C(=C1NC(=O)C2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl)Cl,0
Miquel/Gemma,Anidulafungin,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov097,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O,0
Miquel/Gemma,Gilteritinib,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov098,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5,0
Miquel/Gemma,Berbamine,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov099,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC,0
Miquel/Gemma,Tetrandine,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov100,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,0
Miquel/Gemma,Abemaciclib,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov101,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,0
Miquel/Gemma,Ivacaftor,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov102,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C,0
Miquel/Gemma,Bazedoxifene,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov103,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O,0
Miquel/Gemma,Eltrombopag,Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx,cov104,https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html,,,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C,0
Miquel/Gemma,Tenofovir diphosphate,Inhibition of RdRp in polymerase extension experiment *BioArx,cov105,https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html,,,C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)OP(=O)(O)OP(=O)(O)O,0
Miquel/Gemma,Sofosbuvir,Inhibition of RdRp in polymerase extension experiment *BioArx,cov106,https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html,,,C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3,0
Miquel/Gemma,3’-fluoro-3’-deoxythymidine triphosphate (Alovudine),Inhibition of RdRp in polymerase extension experiment *BioArx,cov107,https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html,,,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)F,0
Miquel/Gemma,3’-azido-3’- deoxythymidine triphosphate (AZT-triP),Inhibition of RdRp in polymerase extension experiment *BioArx,cov108,https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html,,,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N=[N+]=[N-],0
Miquel/Gemma,Atazanavir,"None, computational (MoA: inhibitor 3CLp) *BioArx",cov109,https://www.biorxiv.org/content/10.1101/2020.01.31.929547v1,,,CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,0
Miquel/Gemma,Efavirenz,"None, computational (MoA: inhibitor 3CLp) *BioArx",cov110,https://www.biorxiv.org/content/10.1101/2020.01.31.929547v1,,,C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,0
Miquel/Gemma,Ciclesonide,very small clinical trial with positive outcome,cov111,https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/,,,CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6,3
Victor,Lopinavir,"HIV drug. Combination of Lopinavir, ritonavir and interferon beta is being evaluated in humans",cov112,https://www.nature.com/articles/s41467-019-13940-6,,,CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O,3
Martino,favipiravir,"COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment",cov113,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1,,,C1=C(N=C(C(=O)N1)C(=O)N)F,1
Martino,arbidol,"COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment",cov114,https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1,,,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,0
Victor,Baricitinib,affinity AAK-1 binding drug,cov115,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30304-4/fulltext,,,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,0
Victor,Tocilizumab,"inhibitor of the receptor of interleukin 6 (IL-6), a pro-inflammatory cytokine",cov116,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext,,,,3
Adria,Velpatasvir,NS5A inhibtors in HCV found through Virtual Screening,cov117,https://f1000research.com/articles/9-129/v1,,,CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC,0
Adria,Ledipasvir,NS5A inhibtors in HCV found through Virtual Screening,cov118,https://f1000research.com/articles/9-129/v1,,,CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC,0
Adria,Praziquantel,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov119,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/2,,,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2,0
Adria,Cinacalcet,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov120,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/3,,,CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F,0
Adria,Procainamide,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov121,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/4,,,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,0
Adria,Terbinafine,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov122,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/5,,,CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21,0
Adria,Pethidine,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov123,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/6,,,O=C(C1(CCN(CC1)C)C2=CC=CC=C2)OCC,0
Adria,Labetalol,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov124,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/7,,,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,0
Adria,Tetrahydrozoline,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov125,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/8,,,C1CC(C2=CC=CC=C2C1)C3=NCCN3,0
Adria,Ticlopidine,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov126,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/9,,,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,0
Adria,Ethoheptazine,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov127,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/10,,,CCOC(=O)C1(CCCN(C)CC1)C1=CC=CC=C1,0
Adria,Levamisole,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov128,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/11,,,C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1,0
Adria,Amitriptyline,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov129,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/12,,,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,0
Adria,Naphazoline,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov130,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/13,,,C1CN=C(N1)CC2=CC=CC3=CC=CC=C32,0
Adria,Formoterol,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov131,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/14,,,CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O,0
Adria,Benzylpenicillin,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov132,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/15,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)Cc3ccccc3)C(=O)O)C,0
Adria,Chloroquine,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov133,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/16,,,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,0
Adria,Chlorothiazide,Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.,cov134,https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/17,,,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2,0
Adria,Indinavir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov135,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,0
Adria,Saquinavir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov136,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,0
Adria,Lopinavir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov137,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,0
Adria,Carfilzomib,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov138,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,0
Adria,Remdesivir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov139,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CCC(COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@@]([C@@H]([C@@H]1O)O)(C#N)c1ccc2n1ncnc2N)C)CC,0
Adria,Atazanavir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov140,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC,0
Adria,Darunavir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov141,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,0
Adria,Tipranavir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov142,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CCC[C@]1(CC(/O)=C(\C(=O)O1)[C@H](CC)c3cccc(NS(=O)(=O)c2ccc(cn2)C(F)(F)F)c3)CCc4ccccc4,0
Adria,Fosamprenavir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov143,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N,0
Adria,Enzaplatovir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov144,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,O=C1C2=CC=CN2C[C@@]3(C4=CC=C(C)N=C4)N1CCN3C(C5=CON=C5C)=O,0
Adria,Presatovir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov145,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC1=CN2C(=CC(=N2)C3CCCCN3C(=O)C4=C(C=CC(=C4)Cl)NS(=O)(=O)C)N=C1N5CCC(C5)N,0
Adria,Abacavir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov146,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO,0
Adria,Bortezomib,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov147,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,0
Adria,Elvitegravir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov148,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(C)C(CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O,0
Adria,Maribavir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov149,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(C)NC1=NC2=CC(=C(C=C2N1C3C(C(C(O3)CO)O)O)Cl)Cl,0
Adria,Raltegravir,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov150,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F,0
Adria,Montelukast,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov151,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,0
Adria,Deoxyrhapontin,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov152,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,COC1=CC=C(C=C1)C=CC2=CC(=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O)O,0
Adria,Polydatin,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov153,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,C1=CC(=CC=C1C=CC2=CC(=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O,0
Adria,Chalcone,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov154,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,C1=CC=C(C=C1)C=CC(=O)C2=CC=CC=C2,0
Adria,Disulfiram,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov155,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CCN(CC)C(=S)SSC(=S)N(CC)CC,0
Adria,Carmofur,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov156,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F,0
Adria,Shikonin,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov157,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CC(=CCC(C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C,0
Adria,Ebselen,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov158,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2,0
Adria,Tideglusib,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov159,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43,0
Adria,PX-12,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov160,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CCC(C)SSC1=NC=CN1,0
Adria,TDZD-8,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov161,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CN1SC(N(C1=O)CC2=CC=CC=C2)=O,0
Adria,Cyclosporin A,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov162,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,0
Adria,Cinanserin,Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests ,cov163,https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en,,,CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C2=CC=CC=C2,0
Victor,JQ1,,cov164,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,O=C(OC(C)(C)C)C[C@@H]1N=C(C4=CC=C(Cl)C=C4)C3=C(SC(C)=C3C)N2C1=NN=C2C,0
Victor,RVX-208,,cov165,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,O=C1C2=C(OC)C=C(OC)C=C2NC(C3=CC(C)=C(OCCO)C(C)=C3)=N1,0
Victor,Silmitasertib,,cov166,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4,0
Victor,TMCB,,cov167,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br,0
Victor,Apicidin,,cov168,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CCC(C)C1C(=O)N2CCCCC2C(=O)NC(C(=O)NC(C(=O)N1)CC3=CN(C4=CC=CC=C43)OC)CCCCCC(=O)CC,0
Victor,Valproic Acid,,cov169,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CCCC(CCC)C(=O)O,0
Victor,Bafilomycin A1,,cov170,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CC1CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C2(CC(C(C(O2)C(C)C)C)O)O)O)OC)C,0
Victor,E-52862,,cov171,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CC1=CC(OCCN2CCOCC2)=NN1C1=CC=C2C=CC=CC2=C1,0
Victor,PD-144418,,cov172,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CCCN1CCC=C(C1)C2=CC(=NO2)C3=CC=C(C=C3)C,0
Victor,RS-PPC,,cov173,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,COC(=O)C1(CC1CN2CCC(O)(CC2)c3ccccc3)c4ccc(C)cc4,0
Victor,PB28,,cov174,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,COc1c(CCCC2CCCN3CCN(C4CCCCC4)CC3)c2ccc1,0
Victor,Haloperidol ,,cov175,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3ccc(cc3)Cl)O)F,0
Victor,Entacapone,,cov176,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N,0
Victor,Indomethacin ,,cov177,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,0
Victor,Metformin,,cov178,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CN(C)C(=N)N=C(N)N,0
Victor,Ponatinib ,,cov179,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5,0
Victor,H-89,,cov180,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,O=S(C2=CC=CC1=CN=CC=C12)(NCCNC/C=C/C3=CC=C(Br)C=C3)=O.Cl.Cl,0
Victor,Merimepodib,,cov181,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4,0
Victor,Migalastat,,cov182,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O,0
Victor,Mycophenolic acid,,cov183,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,0
Victor,Ribavirin,,cov184,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,0
Victor,XL413,,cov185,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,ClC1=CC=C2C(C(N=[C@@]([C@H]4NCCC4)NC3=O)=C3O2)=C1.Cl,0
Victor,CCT 365623,,cov186,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CS(=O)(=O)C=1C=C(C=C(C1)C1=CC=CC=C1)S(=O)(=O)C1=CC=C(S1)CN,0
Victor,Midostaurin,,cov187,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC,0
Victor,Ruxolitinib,,cov188,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,0
Victor,ZINC1775962367,,cov189,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,,0
Victor,ZINC4326719,,cov190,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,,0
Victor,ZINC451 1851,,cov191,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,,0
Victor,ZINC95559591,,cov192,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,,0
Victor,AC-55541,,cov193,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,O=C2C1=CC=CC=C1C(C(NC(C3=CC=CC=C3)=O)C(N/N=C(C)/C4=CC=CC(Br)=C4)=O)=NN2,0
Victor,AZ8838,,cov194,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,O[C@H](C1=CC=C(F)C=C1CCC)C2=NC=CN2,0
Victor,Daunorubicin,,cov195,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,0
Victor,GB 110,,cov196,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,,0
Victor,S-verapamil,,cov197,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,0
Victor,AZ3451,,cov198,https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf,,,C[C@H](N1C2=CC=C(C(NC3=CC=C(C#N)C=C3)=O)C=C2N=C1C4=C(C=C5OCOC5=C4)Br)C6CCCCC6,0
Isabelle,BCX4430 (Immucillin-A),inhibition of virus proliferation in cell culture assays using a Vero-E6 cell line infected with MERS-CoV,cov199,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937725/,,,O[C@H]1[C@H](C2=CNC3=C2N=CN=C3N)N[C@H](CO)[C@H]1O,1
,,,cov200,,,,,0
,,,cov201,,,,,0
,,,cov202,,,,,0
,,,cov203,,,,,0
,,,cov204,,,,,
,,,cov205,,,,,
,,,cov206,,,,,
,,,cov207,,,,,
,,,cov208,,,,,
,,,cov209,,,,,
,,,cov210,,,,,
,,,cov211,,,,,
,,,cov212,,,,,
,,,cov213,,,,,
,,,cov214,,,,,
,,,cov215,,,,,
,,,cov216,,,,,
,,,cov217,,,,,
